DBV Technologies (NASDAQ:DBVT) Announces Quarterly Earnings Results

DBV Technologies (NASDAQ:DBVT) issued its quarterly earnings data on Tuesday. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08), Yahoo Finance reports. The company had revenue of $1.16 million for the quarter, compared to the consensus estimate of $1.42 million. DBV Technologies had a negative return on equity of 56.76% and a negative net margin of 530.89%. During the same period in the prior year, the company earned ($0.26) EPS.

DBV Technologies Price Performance

Shares of NASDAQ DBVT traded up $0.00 during midday trading on Wednesday, reaching $0.95. 17,357 shares of the stock were exchanged, compared to its average volume of 55,611. DBV Technologies has a 12 month low of $0.50 and a 12 month high of $3.70. The company has a market capitalization of $91.62 million, a price-to-earnings ratio of -1.13 and a beta of 0.69. The business has a 50-day simple moving average of $0.92 and a two-hundred day simple moving average of $1.33.

Analyst Ratings Changes

DBVT has been the subject of a number of research reports. HC Wainwright lowered their price objective on DBV Technologies from $20.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, May 8th. JMP Securities lifted their target price on shares of DBV Technologies from $4.00 to $5.00 and gave the stock a “market outperform” rating in a report on Wednesday. Finally, StockNews.com assumed coverage on DBV Technologies in a research note on Thursday, July 25th. They issued a “hold” rating on the stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.